Plain-English translation of NCT06039241 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →This is a real-world study that follows patients already taking dupilumab for atopic dermatitis (a chronic skin condition causing itching, redness, and inflammation). Rather than testing whether the medication is safe or effective in a controlled setting, researchers want to understand how well this treatment works in everyday life—what happens to symptoms, quality of life, and skin control over two years in regular medical practice.
While this medication has been approved for atopic dermatitis, doctors need to understand how it performs outside research clinics—whether it works the same way for different age groups, how long patients stay on it, and what long-term safety looks like when real patients take it with all their other health conditions and treatments.
You likely qualify if…
You likely don't qualify if…
You would continue taking dupilumab as prescribed by your doctor and attend regular follow-up visits over two years (or until you stop taking the medication). At these visits, which follow your normal medical care schedule, you'll complete questionnaires about your skin symptoms, how much the condition affects your daily life, and how well the medication is controlling your condition. Researchers will also ask about your medical history, other treatments you're using, and any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany